Chemical Reprogramming of Human Fibroblasts to iPSCs

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for generating human induced pluripotent stem cells (iPSCs) are inefficient, slow, and prone to genetic abnormalities, making them unsuitable for clinical applications.

Innovation Solution

A mixture comprising mammalian cells, a TGFβ receptor/ALK5 inhibitor, a MEK inhibitor, and a Rho GTPase/ROCK pathway inhibitor is used to improve the efficiency of iPSC generation by inhibiting key signaling pathways.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If traditional reprogramming methods are used, then the process can be performed with simple procedures, but the efficiency is low and the process is slow

Engineering Contradiction:

ImproveiPSC generation efficiencyVSAvoidreprogramming process complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent changes the chemical parameters of the reprogramming process by introducing specific pathway inhibitors (TGFβ receptor/ALK5 inhibitor, MEK inhibitor, Rho GTPase/ROCK pathway inhibitor) into the cell culture medium. These chemical modifications enable efficient reprogramming without complex genetic manipulations, resolving the contradiction between efficiency and complexity

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent uses small molecule inhibitors as intermediary substances to mediate the reprogramming process. These inhibitors act as chemical messengers that block specific signaling pathways (TGFβ, MEK, ROCK) and facilitate pluripotency induction, enabling efficient iPSC generation through a simplified procedure

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If reprogramming is performed for extended periods, then more cells can be converted, but genetic abnormalities and tumorigenicity increase

Engineering Contradiction:

ImproveiPSC conversion rateVSAvoidgenetic abnormalities and tumorigenicity

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent maintains continuous inhibition of harmful signaling pathways throughout the reprogramming process using pathway inhibitors. This continuous action prevents the accumulation of genetic abnormalities and tumorigenicity that would otherwise occur during extended reprogramming, while still achieving high conversion rates

Inventive Principle:

Principle #20Continuity of useful action

Solution Approach 2:

The patent converts the potentially harmful effects of prolonged reprogramming (genetic instability, tumorigenicity) into beneficial outcomes by using pathway inhibitors to actively prevent these harmful effects. The inhibitors transform the reprogramming process from a harmful prolonged treatment into a controlled, safe, and efficient procedure

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Productivity

If genetic manipulations are used to improve reprogramming efficiency, then efficiency increases, but the process becomes more complex and risk of genetic alterations increases

Engineering Contradiction:

Improvereprogramming efficiencyVSAvoidgenetic manipulation complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent substitutes the mechanical/genetic manipulation system with a chemical system. Instead of using viral vectors, plasmids, or other genetic delivery methods, the invention employs small molecule pathway inhibitors that chemically block signaling pathways to achieve reprogramming. This replacement eliminates the complexity and risks associated with genetic manipulations while maintaining high efficiency

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Data Source

PatentUS20250136948A1Induction of pluripotent cells

Publication Date: 2025.05.01 THE SCRIPPS RES INST

AI summary

The slow kinetics and low efficiency of reprogramming methods to generate human induced pluripotent stem cells (iPSCs) impose major limitations on their utility in biomedical applications. Here we describe a chemical approach that dramatically improves (>200 fold) the efficiency of iPSC generation from human fibroblasts, within seven days of treatment. This will provide a basis for developing safer, more efficient, non-viral methods for reprogramming human somatic cells.